BELLICUM PHARMACEUTICALS INC (BLCM)
US0794814048 - Common Stock
| MRQ (2023-3-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 15.40M | 21.84M | 46.16M | 35.50M | 91.00M | |||
| Marketable Securities | N/A | N/A | N/A | N/A | 0.00 | |||
| Receivables | 8.00K | 0.00 | 205.00K | 0.00 | 300.00K | |||
| Other Current Assets | 1.83M | 1.96M | 2.77M | 3.90M | 20.50M | |||
| Total Current Assets | 17.24M | 23.80M | 49.13M | 39.40M | 111.90M | |||
| Non-Current Assets | ||||||||
| PPE Net | 24.00K | 22.00K | 12.00K | 800.00K | 3.60M | |||
| Investments And Advances | N/A | N/A | N/A | N/A | N/A | |||
| Other Non-Current Assets | N/A | N/A | 0.00 | 300.00K | 800.00K | |||
| Total Non-Current Assets | 24.00K | 22.00K | 12.00K | 1.20M | 4.40M | |||
| TOTAL ASSETS | 17.26M | 23.82M | 49.14M | 40.60M | 116.30M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | 0.00 | 11.00M | |||
| Accrued Expenses | 3.25M | 2.48M | 3.85M | 5.00M | 10.20M | |||
| Accounts Payable | 1.23M | 486.00K | 90.00K | 900.00K | 2.60M | |||
| Other Current Liabilities | 235.00K | 809.00K | 2.77M | 18.80M | 70.60M | |||
| Total Current Liabilities | 4.72M | 3.77M | 6.71M | 24.70M | 94.40M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 25.70M | |||
| Other Non-Current Liabilities | N/A | N/A | 0.00 | 300.00K | 900.00K | |||
| Total Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 300.00K | 26.60M | |||
| TOTAL LIABILITIES | 4.72M | 3.77M | 6.71M | 25.00M | 121.00M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -583.49M | -575.42M | -550.45M | -540.70M | -533.00M | |||
| Additional Paid In Capital | 578.79M | 582.76M | 580.16M | 543.60M | 511.70M | |||
| Common Shares | 22.66M | 18.12M | 18.12M | 18.10M | 22.00M | |||
| Treasury Stock | -5.06M | -5.06M | -5.06M | -5.10M | -5.10M | |||
| Other Shareholders' Equity | -354.00K | -354.00K | -338.00K | -300.00K | -300.00K | |||
| Shares Outstanding | 9.05M | 8.61M | 8.43M | 8.30M | 5.00M | |||
| Tangible Book Value per Share | -1.11 | 0.23 | 2.89 | -0.30 | -5.24 | |||
| Total Shareholders' Equity | 12.54M | 20.05M | 42.43M | 15.50M | -4.70M | |||
| TOTAL LIABILITIES AND EQUITY | 17.26M | 23.82M | 49.14M | 40.60M | 116.30M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | -5.47 | |||
| Current Ratio | 3.65 | 6.31 | 7.32 | 1.60 | 1.19 | |||
| Return On Assets (ROA) | -147.61% | -104.83% | -19.75% | -19.01% | -96.72% | |||
| Return On Equity (ROE) | -203.10% | -124.55% | -22.87% | -49.81% | N/A | |||
All data in USD